Celon Pharma

Celon Pharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Celon Pharma (CLN.WA) as of Oct 26, 2026 is -56.76 M PLN. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 15.05 M PLN — a change of -477.21% (lower).

EBITDA

-56.76 MPLN

YoY

-477.21%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Celon Pharma is 2025 -56.76 M PLN. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Celon Pharma was 2024 15.05 M PLN. It decreases by -477.21% lower compared to the previous year.

The Celon Pharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
52.83 M PLN
Jan 1, 2019
27.52 M PLN
Jan 1, 2020
30.01 M PLN
Jan 1, 2021
27.81 M PLN
Jan 1, 2022
-25.67 M PLN
Jan 1, 2023
22.77 M PLN
Jan 1, 2024
15.05 M PLN
Jan 1, 2025
-56.76 M PLN
The Celon Pharma EBITDA history
YEAREBITDAYoY
-56.76 MPLN-477.21%
15.05 MPLN-33.92%
22.77 MPLN-188.73%
-25.67 MPLN-192.30%
27.81 MPLN-7.33%
30.01 MPLN+9.05%
27.52 MPLN-47.91%
52.83 MPLN+22.14%
43.25 MPLN-28.40%
60.41 MPLN+9.11%
55.37 MPLN+89.53%
29.21 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celon Pharma Stock analysis

What does Celon Pharma do? Celon Pharma SA develops and manufactures generic drugs for cancer, neurological diseases, diabetes, and metabolic disorders. Its product portfolio includes pills like Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder Salmex. The company operates through its research center focused on oncology, neurology, and inflammatory and metabolic diseases. As a subsidiary of Glatton sp z o o, Celon Pharma SA serves healthcare providers and patients seeking affordable treatment options for chronic conditions. Celon Pharma SA's revenue comes from selling its generic drug portfolio to pharmacies, hospitals, and healthcare institutions. The firm's products target patients with conditions such as cancer, neurological disorders, and diabetes, where cost-effective alternatives are in demand. Glatton sp z o o, the parent company, likely oversees strategic direction and resource allocation for Celon Pharma SA's operations. The company's focus on generic drugs positions it within the pharmaceutical market segment for affordable treatments. Its research center develops new formulations within therapeutic areas like oncology and neurology, supporting ongoing product innovation. Celon Pharma SA's product lineup, including inhalation powder Salmex and pill-based treatments, caters to specific medical needs across multiple disease categories. Celon Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celon Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Celon Pharma is -56.76 M PLN in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Celon Pharma changed from 15.05 M PLN to -56.76 M PLN, representing a -477.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Celon Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Celon Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Celon Pharma

All Key Metrics — Celon Pharma